Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment

Blood

Volumn 127, Issue 6, 2016, Pages 713-721

  Richardson, Paul G ^a   Hungria, Vania T M ^b   Yoon, Sung Soo ^c   Beksac, Meral ^d   Dimopoulos, Meletios Athanasios ^e   Elghandour, Ashraf ^f   Jedrzejczak, Wieslaw W ^g   Guenther, Andreas ^h   Na Nakorn, Thanyaphong ⁱ   Siritanaratkul, Noppadol ^j   Schlossman, Robert L ^a   Hou, Jian ^k   Moreau, Philippe ^l   Lonial, Sagar ^m   Lee, Jae Hoon ⁿ   Einsele, Hermann ^o   Sopala, Monika ^p   Bengoudifa, Bourras Rezki ^p   Corrado, Claudia ^p   Binlich, Florence ^q   San Miguel, Jes̈us F ^r   more..

^a HARVARD UNIVERSITY   (United States)

^b IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

^c Seoul National University College of Medicine   (South Korea)

^d ANKARA UNIVERSITY   (Turkey)

^e UNIVERSITY OF ATHENS   (Greece)

^f ALEXANDRIA UNIVERSITY   (Egypt)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ CHULALONGKORN UNIVERSITY   (Thailand)

^j MAHIDOL UNIVERSITY   (Thailand)

^k SECOND MILITARY MEDICAL UNIVERSITY   (China)

^l NANTES UNIVERSITY HOSPITAL   (France)

^m EMORY UNIVERSITY   (United States)

ⁿ Gachon University   (South Korea)

^o UNIVERSITY OF WÜRZBURG   (Germany)

^p NOVARTIS PHARMA AG   (Switzerland)

^q NOVARTIS PHARMA K K   (Japan)

^r UNIVERSITY CLINIC OF NAVARRA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; PANOBINOSTAT; PLACEBO; THALIDOMIDE; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CEREBROVASCULAR ACCIDENT; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOKALEMIA; INTESTINE ISCHEMIA; LEUKOPENIA; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NECROTIZING FASCIITIS; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; CHEMOTHERAPY, ADJUVANT; DEXAMETHASONE; FEMALE; HUMANS; HYDROXAMIC ACIDS; INDOLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 84959357825     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-665018     Document Type: Article

References (20)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5): 2516-2520.
2. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5): 1122-1128.
3. Kumar SK, Lee JH, Lahuerta JJ, et al; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. 2012;26(1):149-157.
4. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280(2):233-241.
5. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10(11):2034-2042.
6. San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195-1206.
7. Blade J, Samson D, Reece D, et al; Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5): 1115-1123.
8. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26): 2609-2617.
9. Zee B, Cole B, Li T, et al. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol. 1998;16(8):2834-2839.
10. San-Miguel JF, Richardson PG, Gunther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31(29):3696-3703.
11. Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122(14):2331-2337.
12. Stewart AK, Rajkumar SV, Dimopoulos MA, et al; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152.
13. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003- A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14): 2817-2825.
14. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11): 1055-1066.
15. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with lowdose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study. Blood. 2014;123(12):1826-1832.
16. Acaster S, Gaugris S, Velikova G, Yong K, Lloyd AJ. Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: A UK cross-sectional survey. Support Care Cancer. 2013;21(2): 599-607.
17. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28(15):2612-2624.
18. Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica. 2010;95(10):1738-1744.
19. Giver CR, Jaye DL, Waller EK, Kaufman JL, Lonial S. Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia. 2011;25(2): 362-365.
20. Lonial S, Waller EK, Richardson PG, et al; SUMMIT/CREST Investigators. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106(12): 3777-3784.